diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM12978diaendo-12978Research ArticleОригинальные исследованияOriginal StudiesКлинико-эпидемиологические характеристики синдрома гипогонадизма у мужчин с сахарным диабетом 2 типа в Российской Федерации: объединенный анализ данных исследований за период 2005–2022 гг.Clinical and epidemiological characteristics of male hypogonadism in type 2 diabetes in Russia: combined analysis of study data for the period 2005–2022https://orcid.org/0000-0002-7250-4588ЧерноваМ. О.ChernovaM. O.

Чернова Мария Олеговна – аспирант.

117036, Москва, ул. Дм. Ульянова, д. 11

Maria O. Chernova - MD, PhD student.

11 Dm. Ulyanova street, 117036 Moscow

maryblack22@mail.ruhttps://orcid.org/0000-0002-6148-8834ЕсауленкоД. И.EsaulenkoD. I.

Есауленко Дмитрий Игоревич - кандидат медицинских наук.

Воронеж

Dmitry I. Esaulenko - MD, PhD.

Voronezh

desaulenko79@gmail.comhttps://orcid.org/0000-0002-4195-7234РоживановаЕ. Р.RozhivanovaE. R.

Роживанова Екатерина Романовна, клинический ординатор.

Москва

Ekaterina R. Rozhivanovа - clinical resident.

Moscow

erozhivanova@mail.ruhttps://orcid.org/0000-0002-5386-4289РоживановР. В.RozhivanovR. V.

Роживанов Роман Викторович - доктор медицинских наук.

Москва

Roman V. Rozhivanov - MD, PhD.

Moscow

rrozhivanov@mail.ruhttps://orcid.org/0000-0002-5634-7877МельниченкоГ. А.Mel’nichenkoG. A.

Мельниченко Галина Афанасьевна - доктор медицинских наук, профессор, академик РАН.

Москва

Galina A. Mel'nichenko - MD, PhD, Professor, Academician of Russian Academy of Medical Sciences.

Moscow

teofrast2000@mail.ruhttps://orcid.org/0000-0003-3893-9972ШестаковаМ. В.ShestakovaM. V.

Шестакова Марина Владимировна - доктор медицинских наук, профессор, академик РАН.

Москва

Marina V. Shestakova - MD, PhD, Professor, Academician of Russian Academy of Medical Sciences.

Moscow

nephro@endocrincentr.ruhttps://orcid.org/0000-0002-9717-9742МокрышеваН. Г.MokryshevaN. G.

Мокрышева Наталья Георгиевна - доктор медицинских наук, профессор, член-корр. РАН.

Москва

Natalya G. Mokrysheva - MD, PhD, Professor.

Moscow

nm70@mail.ruНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian FederationВоронежский государственный медицинский университет им. Н.Н. БурденкоРоссияVoronezh State Medical UniversityRussian Federation202310022023261412Copyright © Чернова М.О., Есауленко Д.И., Роживанова Е.Р., Роживанов Р.В., Мельниченко Г.А., Шестакова М.В., Мокрышева Н.Г., 20232023Чернова М.О., Есауленко Д.И., Роживанова Е.Р., Роживанов Р.В., Мельниченко Г.А., Шестакова М.В., Мокрышева Н.Г.Chernova M.O., Esaulenko D.I., Rozhivanova E.R., Rozhivanov R.V., Mel’nichenko G.A., Shestakova M.V., Mokrysheva N.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/12978ОБОСНОВАНИЕ

ОБОСНОВАНИЕ. Мужской гипогонадизм ассоциирован с сахарным диабетом 2 типа (СД2), в связи с этим представляет интерес исследование его клинико-эпидемиологических характеристик. Эти данные опубликованы, однако проблемами являются их разрозненность и малые объемы выборок. Суммарная оценка объединенных первичных данных проведенных исследований обеспечит достаточную репрезентативность и позволит экстраполировать результаты на российскую популяцию пациентов с СД2 в целом.

ЦЕЛЬ

ЦЕЛЬ. Оценка клинико-эпидемиологических характеристик и отягощающих факторов синдрома гипогонадизма у мужчин с СД2 в России.

МАТЕРИАЛЫ И МЕТОДЫ

МАТЕРИАЛЫ И МЕТОДЫ. Объединение первичных данных (анамнеза, антропометрических показателей, лабораторного исследования) сплошных одномоментных скрининговых исследований синдрома гипогонадизма у мужчин с СД2, проведенных на территории Российской Федерации в период с 2005 по 2022 гг. Сравнение групп проведено с помощью U-критерия Манна–Уитни и χ² с поправкой Йейтса. Статистически значимыми считались различия при p<0,05.

РЕЗУЛЬТАТЫ

РЕЗУЛЬТАТЫ. Синдром гипогонадизма был выявлен у 893 (56,7%) из 1576 мужчин. Пациенты с гипогонадизмом были статистически значимо старше, имели худшие показатели гликемического контроля и более выраженное ожирение по сравнению с мужчинами без гипогонадизма. При оценке характера осложнений СД2 была выявлена статистически значимо большая распространенность макроангиопатий и полинейропатии у мужчин с гипогонадизмом.

ЗАКЛЮЧЕНИЕ

ЗАКЛЮЧЕНИЕ. Синдром гипогонадизма был выявлен у 56,7% мужчин с СД2. Его развитие обусловлено возрастом, ожирением, нарушением контроля углеводного обмена. Синдром гипогонадизма ассоциирован с развитием диабетических макроангиопатий и полинейропатии. Выраженное нарушение контроля углеводного обмена (гликированный гемоглобин HbA1c 10% и более) усугубляет снижение выработки тестостерона и повышает распространенность гипогонадизма.

Background

Background: Male hypogonadism is associated with type 2 diabetes mellitus (T2DM), therefore, it is of interest to study its clinical and epidemiological characteristics. These data are published, but their fragmentation and small sample sizes are a problem. A summary assessment of the combined primary data of the conducted studies will provide sufficient representativeness and will allow to extrapolate the results to the general Russian population with T2DM.

Aim

Aim: Assessment of the clinical and epidemiological characteristics and aggravating factors of male hypogonadism in T2DM in Russia.

Materials and methods

Materials and methods: A Combining primary data (anamnesis, anthropometric indicators, laboratory tests) of full-design, cross-sectional, screening studies of hypogonadism in men with T2DM conducted on the territory of the Russian Federation in the period from 2005 to 2022. The groups were compared using the Mann-Whitney U-test for quantitative indicators and χ² with Yates’ correction for qualitative ones. Differences were considered statistically significant with p <0,05. The groups were compared using the Mann-Whitney U-test and χ² with Yates correction. Differences were considered statistically significant at p<0.05.

Results

Results: Hypogonadism was detected in 893 of 1576 men (56,7%) with T2DM. Patients with hypogonadism were statistically significantly older, had higher body mass index (BMI), worse glycemic control than eugonadal men. There was ­statistically significantly higher prevalence of macroangiopathies and polyneuropathy in hypogonadal patients.

Conclusion

Conclusion: The prevalence of male hypogonadism in T2DM 56,7%. Its development is due to age, obesity, worse glycemic control. Hypogonadism syndrome is associated with the development of diabetic macroangiopathy and polyneuropathy. Severe violation of glycemic control (glycated hemoglobin (HbA1c) 10% or more) significantly reduces testosterone production and increases the prevalence of hypogonadism.

тестостеронмужчинысиндром гипогонадизмасахарный диабетtestosteronemenhypogonadism syndromediabetes mellitusРабота выполнена по инициативе авторов без привлечения финансированияReferencesMuraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725-733. doi: https://doi.org/10.1530/EJE-13-0321Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725-733. doi: https://doi.org/10.1530/EJE-13-0321Kumari N, Khan A, Shaikh U, et al. Comparison of testosterone levels in patients with and without type 2 diabetes. Cureus. 2021;169(6):725-733. doi: https://doi.org/10.7759/cureus.16288Kumari N, Khan A, Shaikh U, et al. Comparison of testosterone levels in patients with and without type 2 diabetes. Cureus. 2021;169(6):725-733. doi: https://doi.org/10.7759/cureus.16288Li S, Zhao Y, Yang Y, et al. Metabolic effects of testosterone replacement therapy in patients with type 2 diabetes mellitus or metabolic syndrome: A meta-analysis. Int J Endocrinol. 2020;2020:1-12. doi: https://doi.org/10.1155/2020/4732021Li S, Zhao Y, Yang Y, et al. Metabolic effects of testosterone replacement therapy in patients with type 2 diabetes mellitus or metabolic syndrome: A meta-analysis. Int J Endocrinol. 2020;2020:1-12. doi: https://doi.org/10.1155/2020/4732021Дедов И.И., Мельниченко Г.А., Роживанов Р.В., Курбатов Д.Г. Рекомендации по диагностике и лечению дефицита тестостерона (гипогонадизма) у мужчин // Проблемы эндокринологии. — 2016. — Т. 62. — №6. — С. 78-80. doi: https://doi.org/10.14341/probl201662678-80Dedov II, Melnichenko GA, Rozhivanov RV, Kurbatov DG. Guidelines for the diagnosis and treatment of testosterone deficiency (hypogonadism) in male patients. Problems of Endocrinology. 2016;62(6):78-80. (In Russ.). doi: https://doi.org/10.14341/probl201662678-80Dandona P, Dhindsa S, Ghanim H, Saad F. Mechanisms underlying the metabolic actions of testosterone in humans: A narrative review. Diabetes, Obes Metab. 2021;23(1):18-28. doi: https://doi.org/10.1111/dom.14206Dandona P, Dhindsa S, Ghanim H, Saad F. Mechanisms underlying the metabolic actions of testosterone in humans: A narrative review. Diabetes, Obes Metab. 2021;23(1):18-28. doi: https://doi.org/10.1111/dom.14206Lapauw B, Kaufman J-M. Management of endocrine disease: Rationale and current evidence for testosterone therapy in the management of obesity and its complications. Eur J Endocrinol. 2020;183(6):R167-R183. doi: https://doi.org/10.1530/EJE-20-0394Lapauw B, Kaufman J-M. Management of endocrine disease: Rationale and current evidence for testosterone therapy in the management of obesity and its complications. Eur J Endocrinol. 2020;183(6):R167-R183. doi: https://doi.org/10.1530/EJE-20-0394Kumar M, Dutta D, Anne B, et al. Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications. Diabetes, Metab Syndr Obes Targets Ther. 2014;183(6):481. doi: https://doi.org/10.2147/DMSO.S50777Kumar M, Dutta D, Anne B, et al. Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications. Diabetes, Metab Syndr Obes Targets Ther. 2014;183(6):481. doi: https://doi.org/10.2147/DMSO.S50777Хрипун И.А., Воробьев С.В. Влияние тестостерона на функцию эндотелия у мужчин с сахарным диабетом 2 типа // Южно-Российский журнал терапевтической практики. — 2021. — Т. 2. — №3. — С. 78-85. doi: https://doi.org/10.21886/2712-8156-2021-2-3-78-85Khripun IA, Vorobyev SV. Effect of testosterone on endothelial function in men with type 2 diabetes mellitus. South Russ J Ther Pract. 2021;2(3):78-85. (In Russ.). doi: https://doi.org/10.21886/2712-8156-2021-2-3-78-85Демидова Т.Ю., Скуридина Д.В., Касимова А.М. Метаболические и сердечно-сосудистые особенности течения сахарного диабета 2-го типа у мужчин с гипогонадизмом // Медицинский совет. — 2022. — Т. 16. — №10. — С. 34-39. doi: https://doi.org/10.21518/2079-701X-2022-16-10-34-39Demidova TY, Skuridina DV, Kasimova AM. Metabolic and cardiovascular features of the course of type 2 diabetes mellitus in men with hypogonadism. Med Counc. 2022;2(10):34-39. (In Russ.). doi: https://doi.org/10.21518/2079-701X-2022-16-10-34-39Верткин А.Л., Аринина Е.Н., Адонина Е.В. Мужское здоровье: вопросы инволюции и революционные решения // Фарматека. — 2008. — Т. 9. — №163. — С. 39-43.Vertkin AL, Arinina EN, Adonina EV. Muzhskoe zdorov’e: voprosy involiutsii i revoliutsionnye resheniia. Farmateka. 2008;9(163):39-43. (In Russ.).Мамедгасанов Р.М., Мехтиев Т.В. Возрастной андрогенный дефицит и эректильная дисфункция у мужчин репродуктивного возраста с сахарным диабетом 2-го типа // Проблемы эндокринологии. — 2013. — Т. 59. — №1. — С. 3-7. doi: https://doi.org/10.14341/probl20135913-7Mamedgasanov RM, Mekhtiev TV. Age-related androgen deficiency and erectile dysfunction in men of the reproductive age presenting with type 2 diabetes mellitus. Problems of Endocrinology. 2013;59(1):3-7. (In Russ.). doi: https://doi.org/10.14341/probl20135913-7Ding EL, Song Y, Mafk VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes. A systematic review and meta-analysis. JAMA. 2006;295(11):1288-1299. doi: https://doi.org/10.1001/jama.295.11.1288Ding EL, Song Y, Mafk VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes. A systematic review and meta-analysis. JAMA. 2006;295(11):1288-1299. doi: https://doi.org/10.1001/jama.295.11.1288Agarwal P, Singh P, Chowdhury S, et al. A study to evaluate the prevalence of hypogonadism in Indian males with Type-2 diabetes mellitus. Indian J Endocrinol Metab. 2017;21(1):64. doi: https://doi.org/10.4103/2230-8210.196008Agarwal P, Singh P, Chowdhury S, et al. A study to evaluate the prevalence of hypogonadism in Indian males with Type-2 diabetes mellitus. Indian J Endocrinol Metab. 2017;21(1):64. doi: https://doi.org/10.4103/2230-8210.196008Rozhivanov RV, Melnichenko GA, Suntsov YI, Kalinchenko SY. Erectile dysfunction in patients with Diabetes mellitus. Endocrinology (Bulg.). 2006;(2):3-5.Rozhivanov RV, Melnichenko GA, Suntsov YI, Kalinchenko SY. Erectile dysfunction in patients with Diabetes mellitus. Endocrinology (Bulg.). 2006;(2):3-5.Rozhivanov RV, Essaoulenko DI, Kalinchenko SY. The prevalence of hypogonadism in patients with diabetes mellitus type 2 (DMT2). The Aging Male. 2006;9(1):27.Rozhivanov RV, Essaoulenko DI, Kalinchenko SY. The prevalence of hypogonadism in patients with diabetes mellitus type 2 (DMT2). The Aging Male. 2006;9(1):27.Мельниченко Г.А., Шестакова М.В., Роживанов Р.В. Клинико-эпидемиологические характеристики синдрома гипогонадизма у мужчин с сахарным диабетом 2 типа // Сахарный диабет. — 2019. — Т. 22. — №6. — С. 536-541. doi: https://doi.org/10.14341/DM10211Melnichenko GA, Shestakova MV, Rozhivanov RV. The clinical and epidemiological characteristics of hypogonadism in men with type 2 diabetes mellitus. Diabetes Mellitus. 2019;22(6):536-541. (In Russ.). doi: https://doi.org/10.14341/DM10211Есауленко Д.И., Роживанов Р.В., Шишкина В.В., Закурдаев В.А. Дефицит тестостерона при сахарном диабете II типа с разной степенью компенсации углеводного обмена // Саратовский научно-медицинский журнал. — 2022. — Т. 18. — №2. — С. 223-226.Yesaulenko DI, Rozhivanov RV, Shishkina VV, Zakurdaev VA. Testosterone deficiency in type 2 diabetes mellitus with varying degrees of carbohydrate metabolism compensation. Saratov Journal of Medical Scientific Research. 2022;18(2):223-226. (In Russ.).Роживанов Р.В., Чернова М.О., Мельниченко Г.А., и др. Частота встречаемости и отягощающие факторы синдрома гипогонадизма у мужчин с сахарным диабетом 2 типа // Сахарный диабет. — 2022. — Т. 25. — №4. — С. 338-346. doi: https://doi.org/10.14341/DM12913Rozhivanov RV, Chernova MO, Mel’nichenko GA, et al. The incidence and aggravating factors of male hypogonadism in type 2 diabetes. Diabetes mellitus. 2022;25(4):338-346. (In Russ.). doi: https://doi.org/10.14341/DM12913Сахарный диабет: диагностика, лечение, профилактика / Под ред. Дедова И.И., Шестаковой М.В. — М.: ООО Издательство Медицинское информационное агентство; 2011. 801 с.Sakharnyi diabet: diagnostika, lechenie, profilaktika. Ed by Dedov II, Shestakova MV. Moscow: OOO Izdatel’stvo Meditsinskoe informatsionnoe agentstvo; 2011. 801 p. (In Russ.)].Cheung KKT, Luk AOY, So WY, et al. Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence. J Diabetes Investig. 2015;6(2):112-123. doi: https://doi.org/10.1111/jdi.12288Cheung KKT, Luk AOY, So WY, et al. Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence. J Diabetes Investig. 2015;6(2):112-123. doi: https://doi.org/10.1111/jdi.12288Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (10-й выпуск) // Сахарный диабет. — 2021. — Т. 24. — №S1. — С. 1-235. doi: https://doi.org/10.14341/DM12802Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Diabetes Mellitus. 2021;24(S1):1-235 (In Russ.). doi: https://doi.org/10.14341/DM12802Zarotsky V, Huang M-Y, Carman W, et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology. 2014;2(6):819-834. doi: https://doi.org/10.1111/andr.274Zarotsky V, Huang M-Y, Carman W, et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology. 2014;2(6):819-834. doi: https://doi.org/10.1111/andr.274Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts male aging study. J Urol. 1994;151(1):54-61. doi: https://doi.org/10.1016/S0022-5347(17)34871-1Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts male aging study. J Urol. 1994;151(1):54-61. doi: https://doi.org/10.1016/S0022-5347(17)34871-1Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87(2):589-598. doi: https://doi.org/10.1210/jcem.87.2.8201Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87(2):589-598. doi: https://doi.org/10.1210/jcem.87.2.8201Khosla S. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998;83(7):2266-2274. doi: https://doi.org/10.1210/jc.83.7.2266Khosla S. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998;83(7):2266-2274. doi: https://doi.org/10.1210/jc.83.7.2266Vermeulen A. Commentary to the article—low levels of sex hormone-binding globulin and testosterone are associated with smaller, denser low density lipoproteins in normoglycemic men. J Clin Endocrinol Metab. 1998;83(5):1822. doi: https://doi.org/10.1210/jcem.83.5.4821-3Vermeulen A. Commentary to the article—low levels of sex hormone-binding globulin and testosterone are associated with smaller, denser low density lipoproteins in normoglycemic men. J Clin Endocrinol Metab. 1998;83(5):1822. doi: https://doi.org/10.1210/jcem.83.5.4821-3Swerdloff R, Wang K. Androgens and the aging male. Best Practice & Research: Clinical Endocrinology & Metabolism. 2004 Sep;18(3):349-62. doi: https://doi.org/10.1016/j.beem.2004.03.011Swerdloff R, Wang K. Androgens and the aging male. Best Practice & Research: Clinical Endocrinology & Metabolism. 2004 Sep;18(3):349-62. doi: https://doi.org/10.1016/j.beem.2004.03.011Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86(2):724-731. doi: https://doi.org/10.1210/jcem.86.2.7219Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86(2):724-731. doi: https://doi.org/10.1210/jcem.86.2.7219Veldhuis JD, Zwart A, Mulligan T, Iranmanesh A. Muting of androgen negative feedback unveils impoverished gonadotropin-releasing hormone/luteinizing hormone secretory reactivity in healthy older men. J Clin Endocrinol Metab. 2001;86(2):529-535. doi: https://doi.org/10.1210/jcem.86.2.7200Veldhuis JD, Zwart A, Mulligan T, Iranmanesh A. Muting of androgen negative feedback unveils impoverished gonadotropin-releasing hormone/luteinizing hormone secretory reactivity in healthy older men. J Clin Endocrinol Metab. 2001;86(2):529-535. doi: https://doi.org/10.1210/jcem.86.2.7200Spratt DI, Finkelstein JS, Butler JP, et al. Effects of increasing the frequency of low doses of gonadotropin-releasing hormone (gnrh) on gonadotropin secretion in GnRH-deficient men*. J Clin Endocrinol Metab. 1987;64(6):1179-1186. doi: https://doi.org/10.1210/jcem-64-6-1179Spratt DI, Finkelstein JS, Butler JP, et al. Effects of increasing the frequency of low doses of gonadotropin-releasing hormone (gnrh) on gonadotropin secretion in GnRH-deficient men*. J Clin Endocrinol Metab. 1987;64(6):1179-1186. doi: https://doi.org/10.1210/jcem-64-6-1179Veldhuis JD, Urban RJ, Lizarralde G, et al. Attenuation of luteinizing hormone secretory burst amplitude as a proximate basis for the hypoandrogenism of healthy aging in men. J Clin Endocrinol Metab. 1992;75(3):707-713. doi: https://doi.org/10.1210/jcem.75.3.1517359Veldhuis JD, Urban RJ, Lizarralde G, et al. Attenuation of luteinizing hormone secretory burst amplitude as a proximate basis for the hypoandrogenism of healthy aging in men. J Clin Endocrinol Metab. 1992;75(3):707-713. doi: https://doi.org/10.1210/jcem.75.3.1517359Hammar M. Impaired in vitro testicular endocrine function in elderly men. Andrologia. 2009;17(5):444-449. doi: https://doi.org/10.1111/j.1439-0272.1985.tb01039.xHammar M. Impaired in vitro testicular endocrine function in elderly men. Andrologia. 2009;17(5):444-449. doi: https://doi.org/10.1111/j.1439-0272.1985.tb01039.xAntonio L, Wu FCW, O’Neill TW, et al. Associations between sex steroids and the development of metabolic syndrome: A longitudinal study in european men. J Clin Endocrinol Metab. 2015;100(4):1396-1404. doi: https://doi.org/10.1210/jc.2014-4184Antonio L, Wu FCW, O’Neill TW, et al. Associations between sex steroids and the development of metabolic syndrome: A longitudinal study in european men. J Clin Endocrinol Metab. 2015;100(4):1396-1404. doi: https://doi.org/10.1210/jc.2014-4184Савельева Л.В., Роживанов Р.В., Шурдумова Б.О., Фадеев В.В. Нормогонадотропный гипогонадизм у мужчин с ожирением // Ожирение и метаболизм. — 2009. — Т. 6. — №3. — С. 39-42. doi: https://doi.org/10.14341/2071-8713-5243Savel’eva LV, Rozhivanov RV, Shurdumova BO, Fadeev VV. Normogonadotropic hypogonadism in men with obesity. Obesity and metabolism. 2009;6(3):39-42. (In Russ.). doi: https://doi.org/10.14341/2071-8713-5243Dhindsa S, Miller MG, McWhirter CL, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care. 2010;33(6):1186-1192. doi: https://doi.org/10.2337/dc09-1649Dhindsa S, Miller MG, McWhirter CL, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care. 2010;33(6):1186-1192. doi: https://doi.org/10.2337/dc09-1649Vinik AI, Richardson DW. Erectile dysfunction in diabetes. Diabetes Reviews. 1998;(6):16–34.Vinik AI, Richardson DW. Erectile dysfunction in diabetes. Diabetes Reviews. 1998;(6):16–34.Vinik A, Richardson D. Etiology and treatment of erectile failure in diabetes mellitus. Current Diabetes Reports. 2002:2(6):501-509. doi: https://doi.org/10.1007/s11892-002-0120-4Vinik A, Richardson D. Etiology and treatment of erectile failure in diabetes mellitus. Current Diabetes Reports. 2002:2(6):501-509. doi: https://doi.org/10.1007/s11892-002-0120-4Kim SC, Ahn SY, Park SH, et al. A comparison of the relaxation responses of isolated cavernosal smooth muscles by endothelium-independent and endothelium-dependent vasodilators in diabetic men with impotence. J Korean Med Sci. 1995:10(1):1-6. doi: https://doi.org/10.3346/jkms.1995.10.1.1Kim SC, Ahn SY, Park SH, et al. A comparison of the relaxation responses of isolated cavernosal smooth muscles by endothelium-independent and endothelium-dependent vasodilators in diabetic men with impotence. J Korean Med Sci. 1995:10(1):1-6. doi: https://doi.org/10.3346/jkms.1995.10.1.1Cunningham MJ, Clifton DK, Steiner RA. Leptin’s actions on the reproductive axis: perspectives and mechanisms. Biol Reprod. 1999;60(2):216-222. doi: https://doi.org/10.1095/biolreprod60.2.216Cunningham MJ, Clifton DK, Steiner RA. Leptin’s actions on the reproductive axis: perspectives and mechanisms. Biol Reprod. 1999;60(2):216-222. doi: https://doi.org/10.1095/biolreprod60.2.216Ho C-H, Jaw F-S, Wu C-C, et al. The prevalence and the risk factors of testosterone deficiency in newly diagnosed and previously known type 2 diabetic men. J Sex Med. 2015;12(2):389-397. doi: https://doi.org/10.1111/jsm.12777Ho C-H, Jaw F-S, Wu C-C, et al. The prevalence and the risk factors of testosterone deficiency in newly diagnosed and previously known type 2 diabetic men. J Sex Med. 2015;12(2):389-397. doi: https://doi.org/10.1111/jsm.12777Karpova T, de Oliveira AA, Naas H, et al. Blockade of Toll-like receptor 4 (TLR4) reduces oxidative stress and restores phospho-ERK1/2 levels in Leydig cells exposed to high glucose. Life Sci. 2020;(245):117365. doi: https://doi.org/10.1016/j.lfs.2020.117365Karpova T, de Oliveira AA, Naas H, et al. Blockade of Toll-like receptor 4 (TLR4) reduces oxidative stress and restores phospho-ERK1/2 levels in Leydig cells exposed to high glucose. Life Sci. 2020;(245):117365. doi: https://doi.org/10.1016/j.lfs.2020.117365Naas H, de Oliveira AA, Karpova T, Nunes KP. Toll-like receptor 4 (TLR4) as a possible pathological mechanism in hyperglycemia-associated testicular dysfunction. Med Hypotheses. 2019;(127):116-119. doi: https://doi.org/10.1016/j.mehy.2019.04.010Naas H, de Oliveira AA, Karpova T, Nunes KP. Toll-like receptor 4 (TLR4) as a possible pathological mechanism in hyperglycemia-associated testicular dysfunction. Med Hypotheses. 2019;(127):116-119. doi: https://doi.org/10.1016/j.mehy.2019.04.010Shrilatha B. Occurrence of oxidative impairments, response of antioxidant defences and associated biochemical perturbations in male reproductive milieu in the Streptozotocin-diabetic rat. Int J Androl. 2007;30(6):508-518. doi: https://doi.org/10.1111/j.1365-2605.2007.00748.xShrilatha B. Occurrence of oxidative impairments, response of antioxidant defences and associated biochemical perturbations in male reproductive milieu in the Streptozotocin-diabetic rat. Int J Androl. 2007;30(6):508-518. doi: https://doi.org/10.1111/j.1365-2605.2007.00748.xNewsholme P, Haber EP, Hirabara SM, et al. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol. 2007;583(1):9-24. doi: https://doi.org/10.1113/jphysiol.2007.135871Newsholme P, Haber EP, Hirabara SM, et al. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol. 2007;583(1):9-24. doi: https://doi.org/10.1113/jphysiol.2007.135871Dhindsa S, Ghanim H, Batra M, et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care. 2016;39(1):82-91. doi: https://doi.org/10.2337/dc15-1518Dhindsa S, Ghanim H, Batra M, et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care. 2016;39(1):82-91. doi: https://doi.org/10.2337/dc15-1518Xu W, Morford J, Mauvais-Jarvis F. Emerging role of testosterone in pancreatic β cell function and insulin secretion. J Endocrinol. 2019;240(3):R97-R105. doi: https://doi.org/10.1530/JOE-18-0573Xu W, Morford J, Mauvais-Jarvis F. Emerging role of testosterone in pancreatic β cell function and insulin secretion. J Endocrinol. 2019;240(3):R97-R105. doi: https://doi.org/10.1530/JOE-18-0573Olaniyi KS, Badejogbin OC, Saliu SB, Olatunji LA. Rescue effect of sodium acetate in diabetes mellitus-associated testicular dysfunction is accompanied by PCSK9 modulation. Biochimie. 2021;184(3):52-62. doi: https://doi.org/10.1016/j.biochi.2021.02.004Olaniyi KS, Badejogbin OC, Saliu SB, Olatunji LA. Rescue effect of sodium acetate in diabetes mellitus-associated testicular dysfunction is accompanied by PCSK9 modulation. Biochimie. 2021;184(3):52-62. doi: https://doi.org/10.1016/j.biochi.2021.02.004Akinloye O, Blessing Popoola B, Bolanle Ajadi M, et al. Hypogonadism and metabolic syndrome in Nigerian male patients with both type 2 diabetes and hypertension. Int J Endocrinol Metab. 2014;12(1):52-62. doi: https://doi.org/10.5812/ijem.10749Akinloye O, Blessing Popoola B, Bolanle Ajadi M, et al. Hypogonadism and metabolic syndrome in Nigerian male patients with both type 2 diabetes and hypertension. Int J Endocrinol Metab. 2014;12(1):52-62. doi: https://doi.org/10.5812/ijem.10749Blaya R, Thomaz LDGR, Guilhermano F, et al. Total testosterone levels are correlated to metabolic syndrome components. Aging Male. 2016;19(2):85-89. doi: https://doi.org/10.3109/13685538.2016.1154523Blaya R, Thomaz LDGR, Guilhermano F, et al. Total testosterone levels are correlated to metabolic syndrome components. Aging Male. 2016;19(2):85-89. doi: https://doi.org/10.3109/13685538.2016.1154523Mäkinen JI, Perheentupa A, Irjala K, et al. Endogenous testosterone and serum lipids in middle-aged men. Atherosclerosis. 2008;197(2):688-693. doi: https://doi.org/10.1016/j.atherosclerosis.2007.05.009Mäkinen JI, Perheentupa A, Irjala K, et al. Endogenous testosterone and serum lipids in middle-aged men. Atherosclerosis. 2008;197(2):688-693. doi: https://doi.org/10.1016/j.atherosclerosis.2007.05.009Van Pottelbergh I, Braeckman L, De Bacquer D, et al. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis. 2003;166(1):95-102. doi: https://doi.org/10.1016/S0021-9150(02)00308-8Van Pottelbergh I, Braeckman L, De Bacquer D, et al. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis. 2003;166(1):95-102. doi: https://doi.org/10.1016/S0021-9150(02)00308-8Feingold KR, Brinton EA, Grunfeld C. The effect of endocrine disorders on lipids and lipoproteins. In: Endotext [Internet]. South Dartmouth (MA): MDText. com, Inc.; 2020.Feingold KR, Brinton EA, Grunfeld C. The effect of endocrine disorders on lipids and lipoproteins. In: Endotext [Internet]. South Dartmouth (MA): MDText. com, Inc.; 2020.Giatti S, Mastrangelo R, D’Antonio M, et al. Neuroactive steroids and diabetic complications in the nervous system. Front Neuroendocrinol. 2018;(48):58-69. doi: https://doi.org/10.1016/j.yfrne.2017.07.006Giatti S, Mastrangelo R, D’Antonio M, et al. Neuroactive steroids and diabetic complications in the nervous system. Front Neuroendocrinol. 2018;(48):58-69. doi: https://doi.org/10.1016/j.yfrne.2017.07.006Roglio I, Bianchi R, Giatti S, et al. Testosterone derivatives are neuroprotective agents in experimental diabetic neuropathy. Cell Mol Life Sci. 2007;64(9):1158-1168. doi: https://doi.org/10.1007/s00018-007-7002-5Roglio I, Bianchi R, Giatti S, et al. Testosterone derivatives are neuroprotective agents in experimental diabetic neuropathy. Cell Mol Life Sci. 2007;64(9):1158-1168. doi: https://doi.org/10.1007/s00018-007-7002-5

The authors declare that there are no conflicts of interest present.